DESIGN AND DEVELOPMENT OF POLYMERS FOR GENE DELIVERY

Purpose: The lack of safe and efficient gene-delivery methods remains a limiting obstacle to human gene therapy. Synthetic vectors are safer than recombinant viruses but generally lack sufficient efficacy, so polymers must be rationally designed to overcome extracellular and intracellular delivery barriers.

Hypothesis: This is a review article and does not test a single formal hypothesis. Its central premise is that understanding polymer structure–function relationships and the biological barriers to gene delivery will enable the design of synthetic polymers with improved efficacy, biocompatibility, and clinical potential.

Aims: Describe methods of gene delivery and the advantages/disadvantages of viral versus synthetic vectors. - Outline design criteria and biological barriers for non-viral polymeric vectors. - Review “off-the-shelf” gene-delivery polymers: polylysine, polyethyleneimine (PEI), and PAMAM dendrimers. - Review polymers specifically designed for gene delivery, including imidazole-containing polymers, membrane-disruptive peptides/polymers, cyclodextrin-containing polymers, and degradable polycations. - Discuss remaining challenges and future prospects for polymer-based gene therapy.

Delivery system: Vector type: Cationic polymers that self-assemble with DNA/RNA into polyplexes via electrostatic interactions. - Polyplexes: Typically 30 to several hundred nm; often 100–200 nm; composed of several plasmid DNA molecules and hundreds of polymer chains; positive surface charge with excess polycation. - Payloads: Plasmid DNA, antisense oligonucleotides, siRNA. - Off-the-shelf polymers: Polylysine, PEI (linear and branched), PAMAM dendrimers. - Designed polymers: Imidazole-containing polymers (gluconoylated polyhistidine, histidylated polylysine, polylysine-graft-imidazoleacetic acid), pH-responsive membrane-disruptive polymers (PPAA, PAA, PBAA, maleic anhydride copolymers), cyclodextrin-containing polymers, degradable polycations (PAGA, poly(β-amino esters), degradable PEI crosslinks, disulfide-containing poly[Lys-(AEDTP)]). - Targeting ligands: Asialoorosomucoid, transferrin, EGF, antibodies, RGD peptides, folate, sugars. - Shielding agents: PEG, HPMA, oligosaccharides, proteins.

Approach: Review of preclinical in vitro and in vivo literature, plus clinical trial statistics. In vitro models include COS-7, HepG2, 3T3, and other cell lines. In vivo contexts include liver, tumors, CNS, kidney, lung, and wound healing. No new primary experiments are reported.

Key methods: Polyplex formation and characterization; electron microscopy; transfection/gene expression assays; luciferase reporter assays; cytotoxicity assays; haemolysis assays; DNA binding and condensation; endosomal escape; in vivo biodistribution and efficacy.

Key results: PEI: Only 15–20% of amines are protonated at physiological pH, giving strong proton-sponge buffering. - Acetylated PEI: Acetylation of ~43% of primary amines made PEI up to 26-fold more efficient than unmodified PEI. - Fractured PAMAM: Heat/solvolysis-degraded PAMAM showed >50-fold enhanced transfection activity. - Poly[Lys-(AEDTP)]: Disulfide-containing polylysine derivative was 50-fold more efficient than polylysine in HepG2 cells. - PPAA: Approximately 15 times more active than PEAA; maximum haemolytic activity at pH ≤ 6.0. - PAGA: No cytotoxicity under conditions where polylysine reduced cell viability by 80%; with chloroquine, transfected 3-fold better than polylysine. - Degradable PEI crosslinks: Size 14–30 kDa, similar to 25-kDa PEI; mediated 2–16-fold more efficient gene expression and were essentially non-toxic. - Clinical context: 863 gene-therapy clinical trials approved worldwide since 1989; 69% used viral vectors; few successes at the time of review.

Interpretation: Polymeric gene-delivery vectors remain orders of magnitude less efficient than viral vectors, largely because they lack functions to overcome one or more delivery barriers. However, structure–function knowledge from off-the-shelf polymers has enabled rational design of new polymers, and promising candidates are emerging. With improved understanding of polymer gene-delivery mechanisms, polymer-based systems are likely to become an important tool for human gene therapy.

Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Polymer vectors still have poor efficiency compared with viruses. - Many barriers remain poorly characterized, especially cytoplasmic transport and nuclear localization. - Toxicity, in vivo stability, manufacturing reproducibility, and immune responses remain challenges. - Clinical translation is limited; most discussed systems are preclinical. - No large-animal validation or detailed clinical trial data are presented.